Pitch!
Presentations take place in the Biotech Investment Room: drug discovery and delivery companies in all therapeutic areas; and the Technology Investment Room: medical devices, diagnostics, platform technologies and healthcare related product development. Small and medium sized R&D companies looking for investment or collaboration partners are featured.
Applications will open on the 1st September 2021.
First round deadline: 29th October 2021.
To make an informal enquiry email The Anglonordic Conference Team at anglonordic@biopartner.co.uk
A company presentation includes:
-10 minute presentation (includes Q&A).
-One delegate pass, for the Anglonordic Life Science Conference
-Company name on the conference brochure
-Enhanced profile and early access to the 1:1 partnering system
-Company profile featured in the conference programme with speaker photo, and company logo
Additional passes are available - ticket prices to be confirmed.
2021 Investors:
3B Future Health Fund (formerly Helsinn Investment Fund), 4BIO Capital, Advent Life Sciences, Albion Technology & General VCT plc, Alpha Blue Ocean, Alpha Bronze Life Sciences Opportunity Fund, Apollo Ventures, Aratus Capital, Arix Bioscience, Arvic AG, Axilium Holding AB, Axon Capital Partners, BioLucidity Advisors, Bioscience Managers, Biotechnology Business Institute, Bond Asian Ventures Limited, Cascara Ventures Bvba, Catapult Ventures, China Life Franklin Asset Management, Curam Capital Management, DeBere Capital Partners, Deep Science Ventures, Draper Esprit, Eir Ventures, Emerson Collective, ESM Biotech, Esperante, European Investment Bank, GIMV, GL Capital, GreenSky Capital, Hermes Partners Intl Ltd., i2020 Accelerator, Ignite Capital Partners, Inc., Inkef Capital BV, Innovate UK, Inveready Asset Management, IP Group, IPF Partners, Julz Co LLC, Kreos Capital, Kurma Partners SA, Limerston Capital Partners, Longacre Funding Partners Plc, Luminous Ventures, Lundbeckfonden Ventures, M Ventures, Mercia Asset Management, Momentum Biotech, MVM Partners, National Institute for Health Research, NeoMed, New Grounds Venture Capital, Newables and Syndicate Room, Norgine Ventures, Novalis Biotech Acceleration, Novo Holdings, NRW.BANK, o2h Ventures, Optum Ventures, Oxford Technology 3 VCT, Panakes Partners SGRSpa, Pontifax, Questra Limited, RBV Capital, R-Pharm, Rosetta Capital Ltd, Ruffena Capital Ltd, Seroba Life Sciences, Seventure Partners, SHS, SR One, SV Health Investors, Swelife International, Syncona, TRILANTIC EUROPE, UCB Ventures, UK Innovation & Science Seed Fund, V-Bio Ventures, Vickers Venture Partners, Xeraya Capital, and XOventure GmbH.
To view our 2021 Conference Programme and Attendees, click here.
